Registered title, quoted from ClinicalTrials.gov
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
An open trial on glioma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 10 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 10
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteFifth Affiliated Hospital of Sun Yat-sen University中山大学附属第五医院ZhuhaiHospital page
- Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
- Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
- Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
- Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
- Study siteSanbo Brain Hospital, Capital Medical UniversityBeijingHospital page
- Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
- Study siteShenzhen Second People's Hospital深圳市第二人民医院ShenzhenHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteTangdu Hospital空军军医大学唐都医院Xi'anHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07093814, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug.
Inclusion criterion 4
Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106.
Exclusion criterion 3
Women who are breastfeeding.
Exclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07093814, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.
- Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female.
- Diagnosed with recurrent/progressive glioblastoma.
- Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug.
- An expected survival time of≥3 months.
- Have sufficient organ function.
- Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first use of the study drug (if a false-positive pregnancy test result is due to non-pregnancy factors such as illness, further testing via ultrasound or other methods is required, and the investigator must confirm the absence of pregnancy before enrollment).
- Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose.
Exclusion Criteria:
- Patients with extracranial metastases.
- Previously received treatment with oncolytic viruses, gene therapy.
- Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106.
- Subject is known to have an allergic reaction to any of the components of VRT106.
- Patients who can't have a cranial MRI scan.
- Women who are breastfeeding.
Quoted from ClinicalTrials.gov, NCT07093814, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07093814, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.